Early radiologic response after two cycles of neoadjuvant chemoimmunotherapy and pathologic outcomes in resectable non-small cell lung cancer: A multicenter retrospective study
This multicenter retrospective study demonstrates that early radiologic response (CR/PR) after just two cycles of neoadjuvant chemoimmunotherapy strongly predicts favorable pathologic outcomes and survival in resectable non-small cell lung cancer, suggesting that response-adapted treatment duration could be explored in future trials while cautioning against routine shortening outside of controlled settings.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Lung cancer remains the leading cause of cancer-related deaths worldwide, and for tumors that have not spread too far, surgery is the primary way to remove them. However, even after a successful operation, the disease often returns, especially in patients with larger tumors or those involving the lymph nodes. To lower this risk, doctors now often give patients a combination of chemotherapy and immunotherapy before the surgery. This approach, known as neoadjuvant therapy, aims to shrink the tumor and kill hidden cancer cells early on. The standard treatment in major clinical trials has been to give patients three or four rounds of these drugs before operating. Yet, a practical question has lingered: is it necessary to give every patient the full course, or could some patients achieve the same deep benefit with fewer rounds? If a patient's tumor shrinks significantly after just two rounds, could that be a sign that they are ready for surgery, sparing them the extra time, cost, and side effects of additional treatment?
Researchers at three major hospitals in China set out to answer this question by looking back at the records of 330 patients with resectable non-small cell lung cancer who were treated between 2019 and 2025. In this real-world setting, the number of treatment rounds was not decided by a rigid study protocol but was chosen by the medical teams based on how the patients responded. Some patients received two rounds of the drug combination, while others received three or four. The team then compared the results, focusing on two main things: how well the drugs worked to shrink the tumor as seen on scans, and how much cancer remained in the body after the surgery was performed. They also tracked how long patients stayed free of the disease and monitored the side effects of the treatment.
The study found a strong link between what doctors saw on the scans and what they found inside the body during surgery. For patients who received two rounds of treatment, those whose tumors showed a clear response on imaging—meaning the tumor either disappeared completely or shrank significantly—had very high rates of deep pathological response. In plain terms, this means that when the scans showed the tumor was shrinking, the surgery often revealed that the vast majority of the cancer cells had been killed. Specifically, among the patients who responded well after two rounds, nearly three-quarters had a major reduction in cancer cells, and almost half had no detectable cancer cells left at all. Conversely, patients whose tumors did not shrink or even grew during the two rounds were far less likely to have a deep response at the time of surgery.
When the researchers compared the group that received two rounds to the group that received three or four, they observed that the rates of major and complete pathological responses were comparable between the two groups. However, the authors emphasize that because this was not a randomized trial, these comparisons cannot prove that the two-round approach is equivalent to the longer course. The study noted that the shorter course was associated with significantly less bone marrow suppression, a condition where the body's ability to produce blood cells is weakened, compared to those who underwent the longer treatment. While this suggests that for patients who show a strong response early on, stopping at two rounds might reduce the physical toll, the authors caution that these findings do not yet justify changing the standard practice outside of a controlled clinical trial.
Despite these promising findings, the authors are careful not to declare the two-round approach as a new standard of care. The study was retrospective, meaning it looked at past data rather than assigning patients randomly to different treatment lengths. Because of this, the researchers cannot prove that two rounds are exactly equal to three or four for everyone. They noted that about one in four patients who responded well on scans still did not achieve a deep pathological response, and the study only included patients who successfully underwent surgery, excluding those whose disease progressed too quickly to operate. Therefore, the results suggest that early imaging can help identify patients who are likely to benefit from a shorter course, but it does not yet justify routine shortening outside of trials. The findings provide a strong basis for designing future studies to test whether tailoring the treatment duration to the patient's early response can improve outcomes without compromising the cure.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.